Toei Shinyaku Exhibited at the 9th Annual Meeting of the Japanese Society for Preemptive Clinical Medicine and Introduced King Agaricus KA21

Toei Shinyaku exhibited with a booth at the 9th Annual Meeting of the Japanese Society for Preemptive Clinical Medicine, held on November 14–15, 2026, at TODA Hall & Conference Tokyo (Hall B), Tokyo, Japan.

At its booth, the company introduced King Agaricus KA21, its outdoor-grown Agaricus blazei Murill ingredient.

Toei Shinyaku sincerely thanks everyone who visited its booth.

The 9th Annual Meeting of the Japanese Society for Preemptive Clinical Medicine

About Toei Shinyaku Co.,Ltd.

Founded in 1973, Toei Shinyaku is a research-focused manufacturer specializing in Agaricus (Agaricus blazei Murill, also known as Agaricus brasiliensis and Agaricus subrufescens).

The company also manufactures and supplies Agaricus raw materials.

Since 1996, it has been engaged in the research, development and commercialization of King Agaricus KA21 (the KA21 strain).

Through joint research with institutions including Tokyo University of Pharmacy and Life Sciences, Azabu University, Keio University, the National Center for Geriatrics and Gerontology, Juntendo University, the University of Tokyo and Shigakkan University, it has published 34 international papers to date.

It holds six patents in Japan, and its β-glucan measurement technology is also patented in the United States (three patents) and China (one patent).